Japan's Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing deal from Bristol-Myers Squibb that could top out at more than $3.1 billion.

The drug also seemed to retain its efficacy across a range of FRα levels, according to Eisai, which says the ADC seems to target tumour cells that express the antigen on their surfaces ...

For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease that had confounded researchers for more than a century. To assess the ...

GlobalData is the parent company of Clinical Trials Arena. Eisai and Bristol Myers Squibb are running a Phase II trial of its antibody-drug conjugate (ADC) farletuzumab ecteribulin. Although still a ...

Key secondary endpoints such as objective response rate and overall survival were also met. Elahere faces competition from Bristol Myers Squibb and Eisai’s ADC farletuzumab ecteribulin, which is ...

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

Future of Healthcategory Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest July 30, 2024 Businesscategory Shares of Japan's Eisai tumble after EU rejects ...

STOCKHOLM, Nov. 8, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...

Bruce Albala works at Eisai, Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey 07677, United States. Samantha Budd Haeberlein Samantha Budd Haeberlein works at Biogen, 225 Binney Street ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...